Realities of
Retinal Disease
Significant treatment burden plays a strong role in patient outcomes and can impact vision loss. We are committed to doing more for both retina specialists and patients now and in the future.
Realities of
Realities of
Retinal Disease
Significant treatment burden plays a strong role in patient outcomes and can impact vision loss. We are committed to doing more for both retina specialists and patients now and in the future.
THE REALITIES OF CURRENT THERAPIES
People living with retinal diseases often refer to injection frequency as a key limitation of compliance.
These viewpoints of retina specialists are based on the 2020 Preferences and Trends Survey (PAT) from the American Society of Retina Specialists (ASRS).*
of retina specialists believe reduced treatment burden is the greatest unmet need for patients with nAMD
of retina specialists have reported long-acting and sustained delivery as the greatest unmet need for patients with nAMD
of retina specialists consider new treatment MOAs as the greatest unmet need for patients with nAMD
nAMD=neovascular age-related macular degeneration.
*1,003 retina specialists worldwide responded to this survey. The survey questions and categories were adopted by ASRS and were not influenced and/or decided upon by Genentech.
Unmet needs across Ophthalmology
Click on each disease area to learn more about patients’ specific unmet needs in each therapeutic area.
- Requires 8-12 office visits and/or injections per year
- Undiagnosed patients (>50%)
- Slow progression of DR
- Requires 12 office visits and/or injections per year
DME=diabetic macular edema; DR=diabetic retinopathy; RVO=retinal vein occlusion.
Ways Genentech is helping preserve eyesight
Patient-focused
Innovation
Innovation
Through our dedication to innovative drug discovery, biomarker research, digital therapeutics, and novel drug delivery platforms, we strive to design the right therapies for the right patients to create the best patient experience possible
Collaborations With the Ophthalmology Community
We foster extensive collaborations with researchers, clinicians, and patient groups. We have approximately 35 ophthalmologists and retina specialists on staff at Genentech. We hire the best people to advance science and improve people’s lives
Breakthrough
Science
Science
Built on the legacy of Genentech, we are pioneers developing transformative medicines that leverage cutting-edge science to address the highest unmet medical needs for patients